Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Washington Court Hotel

25 sep 2013 8:00 a.m. - 27 sep 2013 5:00 p.m.

525 New Jersey Avenue NW, Washington, DC 20001

DIA/FDA Oligonucleotide-based Therapeutics Conference

Session Chair(s)

James V. McArdle, PHD

James V. McArdle, PHD

President

McArdle & Associates LLC, United States

Speaker(s)

H. Gregg  Claycamp, PHD, MS

ICH Q9 Quality Risk Management: Perspective and Examples

H. Gregg Claycamp, PHD, MS

FDA, United States

Senior Scientist for Risk Analysis and Decision Analysis, ONADE, CVM

Paul  Van Norman

Applications of Risk Assessment in the Manufacturing Development Cycle

Paul Van Norman

NITTO DENKO Avecia, Inc., United States

Director, Manufacturing Operations

Paul  Van Norman

Paul Van Norman

NITTO DENKO Avecia, Inc., United States

Director, Manufacturing Operations

H. Gregg  Claycamp, PHD, MS

Panelist

H. Gregg Claycamp, PHD, MS

FDA, United States

Senior Scientist for Risk Analysis and Decision Analysis, ONADE, CVM

Mohan K. Sapru, PHD, MS

Panelist

Mohan K. Sapru, PHD, MS

FDA, United States

CMC Lead, Office of Pharmaceutical Quality, CDER

Susann  Rosmus

Panelist

Susann Rosmus

Biospring GmbH, Germany

Head of QM

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.